Results 261 to 270 of about 890,466 (364)
Opportunities in Therapeutic mRNA Stabilization: Sequence, Structure, Adjuvants and Vectors
Current mRNA lipid nanoparticles rely on cold storage, which increases the cost and reduces access to the vaccines. As mRNA expands to other clinical opportunities, better methods to stabilize the medicines during shipping, storage, and delivery are needed.
Joshua A. Choe+4 more
wiley +1 more source
ENZYMIC SYNTHESIS OF TRIPHOSPHOPYRIDINE NUCLEOTIDE IN CELL-FREE EXTRACTS
Kurt I. Altman, E. Anthony Evans
openalex +1 more source
New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors
Ross Corriden, P. Insel
semanticscholar +1 more source
FUS Selectively Facilitates circRNAs Packing into Small Extracellular Vesicles within Hypoxia Neuron
This study aimed to unravel the role of FUS in the loading of functional circRNAs into neuronal sEVs under hypoxic conditions, which involves their aggregations in SGs and specific interaction between the FUS Zf_RanBP domain to regulate circRNA sorting in sEVs.
Jiankun Zang+14 more
wiley +1 more source
ISOLATION OF THE RICKETTSIAL INHIBITOR FROM AUTOCLAVED DIPHOSPHOPYRIDINE NUCLEOTIDE
Sheldon Rosenberg, Marianna R. Bovarnick
openalex +1 more source
The study deciphers the landscapes of lineage‐related transcription factors in prostatic adenocarcinoma and neuroendocrine prostate cancer using an innovative approach. These findings, validated across cohorts, highlight TFs' roles in cell development and offer novel therapeutic targets.
Yu Wang+20 more
wiley +1 more source
Wenxiang Meng and colleagues delve into the molecular mechanisms underlying curcumin's modulation of RNA post‐transcriptional N (6)‐methyladenosine (m6A) modification. It is found that curcumin interacts with the Z1‐type protein tyrosine phosphatase receptor (PTPRZ1), maintaining its enzymatic activity and thus regulating the phosphorylation of the m6A‐
Ninan Zhang+9 more
wiley +1 more source
OXIDATION OF REDUCED DIPHOSPHOPYRIDINE NUCLEOTIDE
Karl A. Schellenberg, Leslie Hellerman
openalex +1 more source
Azvudine shows benefits in reducing all‐cause mortality in hospitalized SARS‐CoV‐2 infected patients and liver diseases. COVID‐19 patients with kidney disease and without autoimmune diseases show a preference for azvudine. Azvudine may be a promising antiviral agent for treating COVID‐19 concomitant with liver diseases.
Junyi Sun+18 more
wiley +1 more source